PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

INFLUVAC® TETRA

Quadrivalent influenza vaccine, surface antigen, inactivated
Suspension for Injection

Each 0.5 mL pre-filled syringe contains neuraminidase and 15 mcg haemagglutinin of each virus strain as recommended by the WHO and NACI

Intramuscular injection or deep subcutaneous injection

Active Immunizing Agent for the Prevention of Influenza
ATC Code: J07BB02

BGP Pharma ULC
85 Advance Road
Etobicoke, Ontario
M8Z 2S6

Date of Initial Approval: March 1, 2019

Date of Revision: April 28, 2020

Submission Control No: 238706

©Registered Trademark of BGP Products B.V., licensed use by BGP Pharma ULC, Etobicoke, Ontario, M8Z 2S6
RECENT MAJOR LABEL CHANGES

Strain updates for 2020-2021 influenza season (APR 2020)

TABLE OF CONTENTS

RECENT MAJOR LABEL CHANGES ................................................................. 2
TABLE OF CONTENTS .................................................................................. 2
PART I: HEALTH PROFESSIONAL INFORMATION ...................................... 4
1  INDICATIONS .......................................................................................... 4
   1.1 Pediatrics ............................................................................................ 4
   1.2 Geriatrics ............................................................................................ 4
2  CONTRAINDICATIONS ............................................................................ 4
3  SERIOUS WARNINGS AND PRECAUTIONS BOX .................................... 5
4  DOSAGE AND ADMINISTRATION ............................................................ 5
   4.1 Dosing Considerations ........................................................................ 5
   4.2 Recommended Dose and Dosage Adjustment ...................................... 5
   4.3 Administration .................................................................................... 5
   4.4 Reconstitution .................................................................................... 6
5  OVERDOSAGE .......................................................................................... 6
6  DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .......... 6
7  DESCRIPTION .......................................................................................... 6
8  WARNINGS AND PRECAUTIONS .......................................................... 7
   8.1 Special Populations ............................................................................. 8
      8.1.1 Pregnant Women ........................................................................... 8
      8.1.2 Breast-feeding ............................................................................... 8
      8.1.3 Pediatrics ....................................................................................... 8
      8.1.4 Geriatrics ....................................................................................... 8
9  ADVERSE REACTIONS ............................................................................. 8
   9.1 Adverse Reaction Overview ............................................................... 8
   9.2 Clinical Trial Adverse Reactions ......................................................... 9
   9.6 Post-Market Adverse Reactions ........................................................ 14
10 DRUG INTERACTIONS ............................................................................ 15
   10.3 Drug-Drug Interactions ..................................................................... 15
   10.6 Drug-Laboratory Test Interactions .................................................... 15
11 ACTION AND CLINICAL PHARMACOLOGY ........................................... 15
   11.1 Mechanism of Action ...................................................................... 15
   11.2 Pharmacodynamics .......................................................................... 16
   11.3 Pharmacokinetics ............................................................................. 16
12 STORAGE, STABILITY AND DISPOSAL
13 SPECIAL HANDLING INSTRUCTIONS

PART II: SCIENTIFIC INFORMATION

14 PHARMACEUTICAL INFORMATION

15 CLINICAL TRIALS
   15.1 Trial Design and Study Demographics
   15.2 Study Results

17 NON-CLINICAL TOXICOLOGY

18 SUPPORTING PRODUCT MONOGRAPHS

PATIENT MEDICATION INFORMATION
PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

INFLUVAC® TETRA (quadrivalent influenza vaccine, surface antigen, inactivated) is indicated for the prevention of influenza infection caused by the specific strains contained in the vaccine, in adults and children from 3 years of age and older.

The National Advisory Committee on Immunization (NACI) provides additional guidance on the use of the influenza vaccine in Canada. Please refer to published *Statement on Seasonal Influenza Vaccine* for the current season.

1.1 Pediatrics

**Children (<3 years of age):** The safety and efficacy of INFLUVAC® TETRA in children less than 3 years of age have not been established.

1.2 Geriatrics

**Geriatrics (> 61 years of age):** Studies on healthy elderly showed that INFLUVAC® TETRA is well tolerated. For more details, see **CLINICAL TRIALS**.

2 CONTRAINDICATIONS

INFLUVAC® TETRA is contraindicated in patients who are hypersensitive to the active substances, any ingredient in the formulation that may be present as traces such as eggs, chicken protein (such as ovalbumin), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin as well as any other non-medicinal ingredient, or component of the container. For a complete listing, see **DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**.

Immunization with INFLUVAC® TETRA should be deferred in the presence of febrile illness or acute infection.
3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Not applicable.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

See below.

4.2 Recommended Dose and Dosage Adjustment

The recommended dose of INFLUVAC® TETRA for adults above 18 years is 0.5 mL.

The recommended dose of INFLUVAC® TETRA for children from 3 years of age and older is 0.5 mL. For children less than 9 years of age who have not previously been vaccinated, a second dose of 0.5 mL should be given after an interval of at least 4 weeks.

4.3 Administration

INFLUVAC® TETRA should be administered by intramuscular or deep subcutaneous injection.

Do not administer intravascularly.

INFLUVAC® TETRA is a colourless clear liquid, in pre-filled single-dose syringes with / without a needle.

Parenteral biological products should be inspected visually for extraneous particulate matter and/or discolouration before administration. If these conditions exist, the product should not be administered.

INFLUVAC® TETRA should be allowed to reach room temperature before use.

For syringes without a needle, remove the cap and attach a needle, and bleed the syringe of air while holding the needle pointing vertically upward by pressing the plunger in slowly.

Shake the pre-filled syringe well to uniformly distribute the suspension before administration and remove the needle protection.

Needles should not be recapped, and the syringe should be disposed of properly.

This medicinal product must not be mixed with other medicinal products.

For information on vaccine administration, see the current Canadian Immunization Guide and the Health Canada Website.

The patient should be given a permanent personal immunization record. In addition, it is essential that the physician or nurse record the immunization history in the permanent medical
record of each patient. Thus the permanent office record should contain the name of the vaccine, date given, dose, manufacturer and lot number.

4.4 Reconstitution

INFLUVAC® TETRA comes as 0.5 mL suspension ready for injection.

5 OVERDOSAGE

Overdosage is unlikely to have any untoward effect.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1. – Dosage Forms, Strengths, Composition and Packaging

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength/Composition</th>
<th>Non-medicinal Ingredients</th>
</tr>
</thead>
</table>
| Intramuscular injection or deep subcutaneous injection | 0.5 ml suspension for injection in prefilled syringe with / without needle (glass, type I), containing neuraminidase and 15 mcg haemagglutinin per virus strain, pack of 1 or 10. Not all pack sizes may be marketed. | Excipients
- Calcium chloride dihydrate 0.067 mg
- Disodium phosphate dihydrate 0.67 mg
- Magnesium chloride hexahydrate 0.05 mg
- Potassium chloride 0.1 mg
- Potassium dihydrogen phosphate 0.1 mg
- Sodium chloride 4.0 mg
- Water for Injection To 0.5 mL |
|                          |                                   | Manufacturing Process Residuals
- May also contain trace amounts of cetyltrimethyl ammonium bromide, chicken protein, egg material, formaldehyde, gentamicin sulphate, hydrocortisone, neomycin sulphate*, polymyxin B sulphate*, polysorbate 80, sodium citrate, sucrose, tylosine tartrate.  
- *Only used if gentamicin cannot be used. If not used, not present. |

7 DESCRIPTION

INFLUVAC® TETRA is a quadrivalent subunit influenza vaccine. Each 0.5 mL dose contains neuraminidase and 15 mcg of haemagglutinin antigen for each virus strain present in the vaccine. The composition of INFLUVAC® TETRA is adapted annually to comply with the World Health Organization (WHO) and the National Advisory Committee on Immunization (NACI) recommendations (northern hemisphere).

INFLUVAC® TETRA is a colourless clear liquid. INFLUVAC is thimerosal-free, mercury-free, and contains no preservative.
For the 2020/2021 season, each dose of INFLUVAC® TETRA contains neuraminidase and 15mcg of haemagglutinin of the following virus strains:

- an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
- an A/Hong Kong/2671/2019 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

8 WARNINGS AND PRECAUTIONS

General
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

INFLUVAC® TETRA must not be administered intravascularly.

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.

Sterile epinephrine HCl solution (1:1000) and other appropriate agents should be made available for immediate use in case of an anaphylactic reaction or if acute hypersensitivity to the vaccine occurs. Health care providers should be familiar with current recommendations for the initial management of anaphylaxis in non-hospital settings, including proper airway management.

Before administration of any vaccine, all appropriate precautions should be taken to prevent adverse reactions. This includes a review of the patient’s history with respect to possible hypersensitivity to the vaccine or similar vaccine, determination of previous immunization history, and the presence of any contraindications to immunization, current health status, and a current knowledge of the literature concerning the use of the vaccine under consideration.

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions can occur following, or even before, any vaccination as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from fainted.

INFLUVAC® TETRA should not be administered into the buttocks due to varying amounts of fatty tissue in this region, nor by the intradermal route, since these methods of administration may induce a weaker response.

Influenza virus undergoes significant antigenic changes from time to time, so different vaccines are made every year. INFLUVAC® TETRA, as now constituted, is not effective against all possible strains of influenza virus. Protection is limited to those strains of virus from which the vaccine is prepared or against closely-related strains.

As with any vaccine, immunization with INFLUVAC® TETRA may not protect 100% of susceptible individuals.
INFLUVAC® TETRA contains sodium, less than 1 mmol (23 mg) per dose and potassium, less than 1 mmol (39 mg) per dose.

**Driving and Operating Machinery**
INFLUVAC® TETRA has no or negligible influence on the ability to drive and use machines.

**Hematologic**
Intramuscular injections should be given with care in persons suffering from coagulation disorders or on anticoagulant therapy because of risk of hemorrhage.

**Monitoring and Laboratory Tests**
Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the results. The transient false positive reactions could be due to the IgM response to the vaccine.

**Neurologic**
If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks following previous influenza vaccination, the decision to give INFLUVAC® TETRA should be based on careful consideration of potential benefits and risks (See ADVERSE REACTIONS).

### 8.1 Special Populations

#### 8.1.1 Pregnant Women

Inactivated influenza vaccines, such as INFLUVAC® TETRA, can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of influenza vaccine do not indicate any adverse foetal and maternal outcomes attributable to the vaccine.

#### 8.1.2 Breast-feeding

INFLUVAC® TETRA may be used during breast-feeding.

#### 8.1.3 Pediatrics

**Children (<3 years of age):** The safety and efficacy of INFLUVAC® TETRA in children less than 3 years of age have not been established.

#### 8.1.4 Geriatrics

**Geriatrics (>61 years of age):** Studies on healthy elderly showed that INFLUVAC® TETRA is well tolerated. For more details, see CLINICAL TRIALS.

### 9 ADVERSE REACTIONS

#### 9.1 Adverse Reaction Overview

Safety data regarding the use of INFLUVAC® TETRA are based on two clinical studies; one in healthy adults 18 years of age and older and another in children 3 to 17 years of age.
Undesirable effects observed during the clinical trials were local and systemic adverse reactions, whereby these reactions usually disappeared within 1-2 days without treatment.

The most frequently reported local adverse reaction after vaccination observed in the clinical studies were vaccination site pain in all age groups (16.3% in adults 18 years of age and older to 59.0% in children).

The most frequently reported general adverse reactions after vaccination were:
- Fatigue (11.2%) and headache (10.3%) in adults 18 years of age and above.
- Headache (24.0%) and fatigue (23.6%) in children aged 6 to 17 years.
- Irritability (21.0%) in children aged 3 to 5 years.

See Clinical Trial Adverse Reactions.

There has been no post-marketing exposure to INFLUVAC® TETRA. However, all three of the influenza strains of trivalent influenza vaccine INFLUVAC® are included in INFLUVAC® TETRA. Thus, the adverse reactions reported from post marketing surveillance of trivalent influenza vaccine may also occur in vaccines receiving INFLUVAC® TETRA including allergic reactions in rare cases leading to anaphylactic shock requiring immediate medical help. See Post-Market Adverse Reactions.

9.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another vaccine. Adverse reaction information from clinical trials is useful for identifying vaccine-related adverse events and for approximating rates.

Safety data regarding the use of INFLUVAC® TETRA are based on two clinical studies. Both were randomized, double-blind, active-controlled studies to assess the safety and immunogenicity of INFLUVAC® TETRA (QIV) and its noninferiority to INFLUVAC® (TIV). In healthy adults 18 years of age and older, QIV was administered to 1,535 subjects, and 221 subjects each received the TIV formulation containing a B-strain of the Yamagata lineage (TIV\(_{\text{Yam}}\)) and the TIV formulation containing a B-strain of the Victoria lineage (TIV\(_{\text{Vic}}\)). In children and adolescents from 3 to 17 years of age, the study enrolled primed subjects, i.e., children and adolescents aged 9 to 17 years as well as those aged 3 to 8 years who had received ≥ two doses of a seasonal influenza vaccine at least one month apart; and unprimed subjects, i.e., children aged 3 to 8 years who had not previously received ≥ 2 doses of a seasonal influenza vaccine at least one month apart. Primed subjects were administered a single dose. Unprimed subjects were administered two doses 4 weeks apart. The number of subjects that were vaccinated is 1,200 in total (804 primed subjects and 396 unprimed subjects): 402 for QIV, 404 for TIV\(_{\text{Vic}}\), 394 for TIV\(_{\text{Yam}}\).

Adults 18 years of age and older:

Solicited events for local and systemic reactogenicity were collected for 7 days (day of vaccination and the next 6 days) and unsolicited adverse events were collected up to 6 months (all adverse events up to Day 22, serious adverse events and new chronical illnesses (NCIs) between Day 22 and Day 183).

The most frequently reported solicited adverse reactions after vaccination observed in the clinical study for INFLUVAC® TETRA were vaccination site pain (16.3%) [for local reactions]
(see Table 2) as well as fatigue (11.2%) and headache (10.3%) [for general reactions].

The incidence of solicited local and systemic reactions in adults, 18 years of age and older in the two study arms as well as the corresponding numbers derived from the INFLUVAC® safety database is presented in Table 2. This safety database consists of 16 clinical trials for the current thimerosal-free vaccine formulation INFLUVAC® (introduced in 2004; reactogenicity was evaluated in 3217 subjects, of whom 1473 were adults and 1744 subjects over 60 years of age.)

Table 2. - Incidence of solicited local and systemic reactions in Study INFQ3001 and the INFLUVAC® database in combined age groups (adults 18-60 years of age and elderly ≥61 years of age) within 7 days of vaccinationa (Total vaccinated Cohort)

<table>
<thead>
<tr>
<th>Study INFQ3001</th>
<th>INFLUVAC® TETRA</th>
<th>INFLUVAC® (TIV)</th>
<th>INFLUVAC® (TIV) Databaseb</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=1531</td>
<td>N=441</td>
<td>N=3217</td>
<td></td>
</tr>
<tr>
<td>Any Grade</td>
<td>Grade 3c</td>
<td>Any Grade</td>
<td>Grade 3c</td>
</tr>
<tr>
<td>Local</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema</td>
<td>3.1%</td>
<td>-</td>
<td>2.5%</td>
</tr>
<tr>
<td>Swelling</td>
<td>5.0%</td>
<td>0.1%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Induration</td>
<td>4.4%</td>
<td>0.1%</td>
<td>4.5%</td>
</tr>
<tr>
<td>Vaccination Site Pain</td>
<td>16.3%</td>
<td>0.1%</td>
<td>12.7%</td>
</tr>
<tr>
<td>Ecchymosis</td>
<td>2.7%</td>
<td>-</td>
<td>1.4%</td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>10.3%</td>
<td>0.2%</td>
<td>8.8%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>11.2%</td>
<td>0.5%</td>
<td>12.3%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>7.4%</td>
<td>0.3%</td>
<td>6.8%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5.2%</td>
<td>0.3%</td>
<td>3.4%</td>
</tr>
<tr>
<td>Malaise</td>
<td>6.1%</td>
<td>0.3%</td>
<td>7.7%</td>
</tr>
<tr>
<td>Sweating</td>
<td>5.2%</td>
<td>0.1%</td>
<td>5.7%</td>
</tr>
<tr>
<td>Shivering</td>
<td>3.9%</td>
<td>0.2%</td>
<td>3.4%</td>
</tr>
<tr>
<td>Fever</td>
<td>0.5%</td>
<td>0.2%</td>
<td>0.6%</td>
</tr>
</tbody>
</table>

N: number of subjects in the safety sample
a. Local and systemic solicited events within 7 days; results shown are the maximum ratings from Day 1 to Day 7.
b. The safety database of trivalent INFLUVAC® consists of subjects from 16 clinical trials vaccinated with the thimerosal-free formulation comparable to the INFLUVAC® TETRA and the INFLUVAC® as used in study INFQ3001; there were 1,473 adults and 1,744 elderly subjects in the pooled safety sample; solicited events were coded in the same manner in the studies as well as study INFQ3001.
c. Grade 3 pain: Prevents normal daily activity.
Grade 3 redness, swelling: >10 cm.
Grade 3 swelling: > 10 cm or prevents normal daily activity.
Grade 3 muscle aches, headache, fatigue, myalgia, arthralgia, malaises, shivering: Prevents normal daily activity.
Grade 3 sweating: Prevents normal daily activity.
Grade 3 fever: Defined as >39°C.

These reactions usually disappear within 1-2 days without treatment.
In the clinical study for INFLUVAC® TETRA, all reporting rates in non-elderly adult subjects were lower than 10%, except for the local reaction of vaccination site pain (24.9% [QIV] versus 18.5% [TIV]), and the systemic reactions of headache (12.4% [QIV] versus 13.1% [TIV]) and fatigue/tiredness (11.9% [QIV] versus 12.6% [TIV]). The vast majority of the vaccination site pain reactions were reported within the first three days in both QIV and TIV groups and were mostly rated as mild (> 90%). Only one case was rated as severe (grade 3 toxicity grading) in the QIV group. In addition, for other local and systemic reactions, there were no relevant differences in reporting duration or severity grading; grade 3 (severe) reporting for each of the reactions was low, both for systemic (≤ 0.3% in the QIV group and ≤0.9% in the TIV group) and local reactions (≤ 0.1% in the QIV group and 0 in the TIV group).

In elderly subjects, reporting rates of all local reactions were low in both vaccination groups, fell below 5%, except for vaccination site pain (7.6% [QIV] versus 5.9% [TIV]). For systemic reactions, fatigue/tiredness was reported by 10.6% and 6.8%; headache by 8.1% and 7.3%; arthralgia/joint pain by 5.8% and 2.3% of subjects in the QIV group and the TIV group, respectively. Grade 3 (severe) reporting for each of the reactions was low, both for systemic (≤ 0.7% in the QIV group and ≤ 0.5% in the TIV group) and local reactions (≤ 0.1% in the QIV group and ≤ 0.9% in the TIV group).

Although a slight increase in systemic reactions in elderly subjects due to a higher HA content cannot be excluded based on the above, this is not confirmed in adult subjects, where no flagging occurred. In addition, in terms of severity and duration of reactions, there were no marked differences between the QIV and TIV groups for any of the reactions in either adult or elderly subjects.

Overall, reporting rates of local reactions showed a tendency of being higher in adult subjects than in elderly subjects in both QIV and TIV groups, which is in line with historical data.

In general, reactions were reported within the first three days after vaccination. Only a few subjects reported systemic or local reactions beyond seven days (3 subjects for each [0.2%] in the QIV group versus 2 subjects each [0.5%] in the TIV group).

Unsolicited events reported for INFLUVAC® TETRA: Up to Day 22, 4.8% of adults (n=37) and 3.8% of elderly (n=29) reported at least one treatment-emergent adverse event (TEAE, adverse event that started or worsened in severity on or after the first study vaccination). 0.5% of adults and 0.8% of elderly had at least one TEAE that was considered to have a reasonable possibility for a causal relationship with the study vaccine as judged by the investigator. Events were asthenia (n=2), diarrhea and syncope (both n=1) reported in adults, and myalgia, musculoskeletal stiffness, vertigo, chills, nasopharyngitis and dizziness (all n=1) reported in elderly. No deaths were reported, and none of the subjects experienced TEAEs that led to study termination up to the Day 22 visit.

Between Day 22 and Day 183, 1.3% of adults (n=10) and 3.9% of elderly (n=30) reported at least one treatment-emergent serious adverse event (TESAE, including new chronic illnesses, NCIs). None of the TESAEs were considered to have a reasonable possibility for a causal relationship with the study vaccine by the investigator. Non-serious NCIs were reported in 1.3% of adults (n=10) and 4.0% of elderly (n=31). None of the NCIs were considered to have a reasonable possibility for a causal relationship with the study vaccine by the investigator.
Children and adolescents from 3 to 17 years of age:

The most frequently reported general adverse reactions after vaccination were headache (24.0%) and fatigue (23.6%) in children aged 6 to 17 years and irritability (21.0%) in children aged 3 to 5 years of age. The most frequently reported local adverse reaction after vaccination was vaccination site pain in all age groups (59.0%).

The incidence of solicited local and systemic reactions in children is presented in Table 2a.

Table 2a. - Incidence of solicited local and systemic reactions in Study INFQ3002

<table>
<thead>
<tr>
<th></th>
<th>Study INFQ3002</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>INFLUVC® TETRA</td>
<td>INFLUVC® (TIV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=402</td>
<td>N=798</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any Grade</td>
<td>Grade 3*</td>
<td>Any Grade</td>
<td>Grade 3*</td>
<td></td>
</tr>
<tr>
<td><strong>Local</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>59.0%</td>
<td>1.7%</td>
<td>52.3%</td>
<td>1.3%</td>
<td></td>
</tr>
<tr>
<td>Redness</td>
<td>19.4%</td>
<td>4.0%</td>
<td>16.7%</td>
<td>3.9%</td>
<td></td>
</tr>
<tr>
<td>Swelling</td>
<td>13.4%</td>
<td>2.5%</td>
<td>10.7%</td>
<td>2.4%</td>
<td></td>
</tr>
<tr>
<td>Induration</td>
<td>11.4%</td>
<td>0.7%</td>
<td>10.1%</td>
<td>1.5%</td>
<td></td>
</tr>
<tr>
<td>Ecchymosis</td>
<td>6.4%</td>
<td>0.2%</td>
<td>4.6%</td>
<td>0.3%</td>
<td></td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>24.0%</td>
<td>-</td>
<td>20.9%</td>
<td>1.2%</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>23.6%</td>
<td>0.9%</td>
<td>22.1%</td>
<td>0.4%</td>
<td></td>
</tr>
<tr>
<td>Irritability</td>
<td>21.0%</td>
<td>1.1%</td>
<td>17.8%</td>
<td>0.3%</td>
<td></td>
</tr>
<tr>
<td>Drowsiness</td>
<td>15.9%</td>
<td>1.1%</td>
<td>12.7%</td>
<td>0.3%</td>
<td></td>
</tr>
<tr>
<td>Appetite loss</td>
<td>13.1%</td>
<td>1.1%</td>
<td>11.1%</td>
<td>0.6%</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal symptoms</td>
<td>14.8%</td>
<td>0.4%</td>
<td>10.0%</td>
<td>0.2%</td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>14.8%</td>
<td>0.4%</td>
<td>15.3%</td>
<td>0.8%</td>
<td></td>
</tr>
<tr>
<td>Malaise</td>
<td>14.8%</td>
<td>0.9%</td>
<td>12.3%</td>
<td>0.6%</td>
<td></td>
</tr>
<tr>
<td>Sweating</td>
<td>4.2%</td>
<td>0.5%</td>
<td>3.7%</td>
<td>0.3%</td>
<td></td>
</tr>
<tr>
<td>Diarrhea/ vomiting</td>
<td>6.8%</td>
<td>-</td>
<td>7.3%</td>
<td>0.6%</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>6.1%</td>
<td>-</td>
<td>4.9%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Shivering</td>
<td>4.4%</td>
<td>0.4%</td>
<td>3.5%</td>
<td>0.2%</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>4.2%</td>
<td>0.7%</td>
<td>2.6%</td>
<td>0.4%</td>
<td></td>
</tr>
</tbody>
</table>

*Grade 3:
Vaccination site pain: Cries when arm is moved/ spontaneously painful (for children 3 to 5 years of age); Pain that prevents normal daily activity (for children 6 years of age and older).
Vaccination site redness, swelling, induration, ecchymosis: > 10 cm
Headache, fatigue: Prevents normal daily activity
Irritability (for children 3 to 5 years of age): Crying that cannot be comforted/ prevents normal daily activity
Drowsiness (for children 3 to 5 years of age): Prevents normal daily activity
Appetite loss (for children 3 to 5 years of age): Not eating at all
Gastrointestinal symptoms (nausea, vomiting, diarrhea and/or abdominal pain), diarrhea/ vomiting (for children 3 to 5 years of age): Prevents normal daily activity
Myalgia, malaise, sweating, arthralgia, shivering: Prevents normal daily activity
Fever: Temperature (measured by oral or rectal method) > 39.0°C

N: number of subjects in the safety sample
Local Reactions:
Overall, the proportion of subjects with any local reaction was 62.7% with the QIV formulation and 57.9% with the TIV formulation. This was not shown consistently between age groups; a proportion of subjects aged 3 to 8 years reported local reactions was 65.4% in the QIV group and 55.6% in the TIV group, while a proportion of subjects aged 9 to 17 years reported any local reaction was 62.8% in the TIV group and 57.9% in the QIV group.

All local reactions were reported with an incidence rate of less than 20%, with the exception of vaccination site pain, reported for 59.0% in the QIV group and 52.5% in the TIV group.

In primed subjects 3 to 8 years of age, this difference between QIV and TIV for vaccination site pain was most pronounced (60.9% and 48.5%, respectively). In unprimed subjects 3 to 8 years of age the incidence rate was 61.8% in the QIV group and 50.2% in the TIV group. In subjects aged 9 to 17 years, the vaccination site pain was reported by 54.1% in the QIV group and 58.7% in the TIV group. The majority of local reactions were not severe. A comparable proportion of subjects with severe local reactions of each type were reported between the QIV and TIV groups.

Overall, all local reaction symptoms lasted for 1 to 3 days for the majority of subjects, with the exception of vaccination site ecchymosis lasting 1 to 7 days in the QIV as well as TIV group. Symptoms lasting ≥ 7 days in the QIV group were Vaccination site pain (0.8%), Vaccination site erythema (1.3%), Swelling (1.9%), induration (4.3%) and Vaccination site ecchymosis (19.2%). In the TIV group these percentages were 2.6%, 3.0%, 5.9%, 2.5% and 8.3% respectively.

Unprimed subjects were provided a second diary when receiving the second vaccination. For the majority of subjects and each reaction (>80% in both QIV and TIV groups), vaccinations were considered the same with respect to severity and duration.

Systemic Reactions:
The same proportion of subjects (38.1%) in both the QIV and TIV groups had any systemic reaction during the study. In the different subgroups, however, the proportion of subjects with systemic reactions in the QIV group was numerically higher than in the TIV group for unprimed subjects aged 3 to 8 years (41.9% versus 38.2%) and aged 9 to 17 years (47.4% versus 44.6%), whereas in primed subjects aged 3 to 8 years, the proportion in the QIV group was numerically lower than in the TIV group (24.8% versus 31.5%).

The most commonly reported systemic reaction was fatigue/tiredness, with a reporting rate of 23.6% and 22.1% in the QIV and TIV groups, respectively, followed by headache, with a reporting rate of 24.0% and 20.9% in the QIV and TIV groups, respectively. All other systemic reactions were reported with an incidence rate of less than 20%. The majority of systemic reactions were mild to moderate in both the QIV and TIV group.

Overall, all systemic reaction symptoms lasted for 1 to 2 days for the majority of subjects. For QIV, no reactions were present beyond 7 days for diarrhea/vomiting, loss of appetite, myalgia, arthralgia, sweating and shivering; 2-4% for irritability, drowsiness, headache and gastrointestinal symptoms; and 5-8% for fever, fatigue, malaise.
During Period 1 (immunization period, up to and including Day 29/Day 57), the proportion of subjects with at least 1 Treatment-Emergent Adverse Event (TEAE) was 18.9% in the QIV group and 22.6% in the TIV groups. The number of subjects with at least 1 TEAE considered to have a reasonable possibility for a causal relationship (i.e., drug-event relationship reported as possible, probable, or missing) was 0.7% and 1.5% of subjects in the QIV and TIV groups, respectively. Overall, 0.7% and 0.5% of subjects in the QIV and TIV groups had a severe TEAE, respectively.

Six subjects (0.5%) had at least 1 Treatment-Emergent Serious Adverse Event (TESAE) during Period 1 of the study: 2 subjects (0.5%) and 4 subjects (0.5%) in the QIV and TIV groups, respectively. None of the TESAEs were considered to have a reasonable possibility for a causal relationship with the study vaccine.

During Period 2 (safety follow-up period, up to 6 months) of the study, 2 subjects (0.5%) in the QIV group and 4 subjects (0.5%) in the TIV group had at least 1 TESAE. Gastroenteritis was reported for 3 subjects (0.4%) in the TIV group. All other PTs were reported for 1 subject each. None of the TESAEs were considered to have a reasonable possibility for a causal relationship with the study vaccine.

New Chronic Illnesses (NCI) were recorded during Period 2 for 3 subjects (0.4%) vaccinated with TIV formulations; there were no NCIs in the QIV group. The PTs reported were asthma, Henoch-Schönlein purpura (also reported as an SAE), and essential hypertension. The events of Henoch-Schönlein purpura and essential hypertension were considered as unrelated to study vaccine; the event of asthma was considered as unlikely to have a causal relationship to the study vaccine.

There were no deaths during this study.

9.6 Post-Market Adverse Reactions

There has been no post-marketing exposure to INFLUVAC® TETRA. However, as all three of the influenza strains of trivalent influenza vaccine are included in INFLUVAC® TETRA, the following adverse reactions reported from post marketing surveillance (in addition to reactions which have also been observed during clinical trials) of trivalent influenza vaccine (INFLUVAC®) may occur also in individuals receiving INFLUVAC® TETRA.

Blood and lymphatic system disorders:
- Transient thrombocytopenia, transient lymphadenopathy

Immune system disorders:
- Allergic reactions, in rare cases leading to shock, angioedema

Nervous system disorders:
- Neuralgia, paraesthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome

Guillain-Barré Syndrome (GBS) occurred in adults in association with the 1976 swine influenza vaccine, and evidence favours the existence of a causal relation between the vaccine and GBS during that season. In an extensive review of studies since 1976, the United States Institute of
Medicine concluded that the evidence is inadequate to accept or reject a causal relation between GBS in adults and influenza vaccines administered after the swine influenza vaccine program in 1976.

In Canada the background incidence of GBS was estimated at just over 20 cases per million population in a study done in Ontario and Quebec. A variety of infectious agents, such as Campylobacter jejuni, have been associated with GBS. It is not known whether influenza virus infection itself is associated with GBS. Neither is it known whether influenza vaccination is causally associated with increased risk of recurrent GBS in persons with a previous history of GBS. Avoiding subsequent influenza vaccination of persons known to have developed GBS within 6 to 8 weeks of a previous influenza vaccination appears prudent at this time. The reporting rate of GBS associated with INFLUVAC is concluded to remain within the expected back-ground incidence.

**Vascular disorders:**
Vasculitis associated in very rare cases with transient renal involvement

**Skin and subcutaneous tissue disorders:**
Generalized skin reactions including pruritus, urticaria or non-specific rash

Physicians, nurses and pharmacists should report any immediate adverse reactions arising from any vaccination, or following shortly thereafter, in accordance with local requirements and to the manufacturer: Drug Safety, BGP Pharma ULC, 85 Advance Rd., Etobicoke, ON M8Z 2S6 Canada. Telephone: 1-844-596-9526.

### 10 DRUG INTERACTIONS

#### 10.3 Drug-Drug Interactions

No data are available to address the concomitant use of INFLUVAC® TETRA with other vaccines. When INFLUVAC® TETRA is given at the same time as other vaccines, immunization should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.

The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.

#### 10.6 Drug-Laboratory Test Interactions

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the results. The transient false positive reactions could be due to the IgM response by the vaccine.

### 11 ACTION AND CLINICAL PHARMACOLOGY

#### 11.1 Mechanism of Action

INFLUVAC® TETRA provides active immunisation against four influenza virus strains (two A
subtypes and two B subtypes) contained in the vaccine. INFLUVAC® TETRA, induces humoral antibodies against the haemagglutinins. These antibodies neutralise influenza viruses.

Specific levels of hemagglutination-inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titers have been used as a measure of vaccine activity.

Protective antibody levels (seroprotection) are generally obtained within 2 to 3 weeks after vaccination. The duration of postvaccinal immunity varies but is usually 6-12 months.

Influenza A viruses are classified into subtypes on the basis of 2 surface antigens: hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin (H1, H2, H3) and 2 subtypes of neuraminidase (N1, N2) are recognized among influenza A viruses that have caused widespread human disease. Immunity to these antigens, especially to the hemagglutinin, reduces the likelihood of infection and lessens the severity of disease if infection occurs. Infection with a virus of one subtype confers little or no protection against viruses of other subtypes. Antigenic variation over time within a subtype may be so marked that infection or vaccination with one strain may not induce immunity to distantly related strains of the same subtype. Influenza B viruses can be further classified into two lineages: B/Yamagata and B/Victoria. Although influenza B viruses have shown more antigenic stability than influenza A viruses, antigenic variation does occur. For these reasons, major epidemics of respiratory disease caused by variants of influenza still occur. The antigenic characteristics of current and emerging influenza virus strains provide the basis for selecting the virus strains included in each year's vaccine.

### 11.2 Pharmacodynamics

See Section 15.2 Study Results.

### 11.3 Pharmacokinetics

As a vaccine product, pharmacokinetic studies are not applicable.

### 12 STORAGE, STABILITY AND DISPOSAL

INFLUVAC® TETRA should be stored at 2 to 8°C (in a refrigerator). Do not freeze. Store in the original package in order to protect from light.

Do not use vaccine after expiration date as stated on the label.

### 13 SPECIAL HANDLING INSTRUCTIONS

INFLUVAC® TETRA should be allowed to reach room temperature before use. Shake well before use. Inspect visually prior to administration (See Administration).

Any unused product or waste material should be disposed of in accordance with local requirements.
PART II: SCIENTIFIC INFORMATION

14 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Quadrivalent influenza virus subunit vaccine (surface antigen, inactivated).

Chemical name: Monovalent Bulk containing inactivated hemagglutinin and neuraminidase surface antigens of WHO/NACI recommended strains of influenza virus.

Physicochemical properties: The Monovalent Bulk is a clear to slightly opalescent liquid. The pH of the Monovalent Bulk is in the range 6.9 to 7.5.

Product Characteristics

This vaccine complies with the WHO and NACI recommendations (northern hemisphere) for the 2020-2021 season. The active substances are:

Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains:

• A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like strain (A/Guangdong-Maonan/SWL1536/2019, CNIC-1909)
• A/Hong Kong/2671/2019 (H3N2)-like strain (A/Hong Kong/2671/2019, IVR-208)
• B/Washington/02/2019-like strain (B/Washington/02/2019, wild type)
• B/Phuket/3073/2013-like strain (B/Phuket/3073/2013, wild type)

The virus strain is supplied as a primary seed virus by the NIBSC (National Institute for Biological Standards and Control, Potters Bar, UK), or by another designated WHO laboratory. The primary seed virus is propagated in embryonated SPF (specific pathogen-free) hens’ eggs to generate a master seed virus (MSV). The working seed virus (WSV) is generated by the propagation of the MSV in embryonated SPF hens’ eggs.

The WSV is diluted to a seed suspension and then inoculated in embryonated eggs. The inoculated eggs are incubated for approximately 3 days. After incubation, the eggs are cooled to 5 ± 3°C for 4 - 48 hours.

The allantoic fluid is harvested from the eggs and clarified using a centrifuge to remove cell and egg debris. The clarified allantoic fluid of the single harvest of a strain is separated in a zonal gradient centrifuge (0-60% sucrose). The virus containing fractions with approximately 47 to 35% m/m of sucrose are collected and inactivated by formaldehyde treatment in two stages, first for 18 hours to 3 days and secondly for 4 to 10 days. The inactivated fractions are pooled, filtered and diluted with PBS. The sucrose and formaldehyde is removed by ultrafiltration. The hemagglutinin and neuraminidase are solubilised by the addition of Polysorbate 80 and CTAB. The non-solubilised remainders of the virus particles are removed by centrifugation.

The CTAB and the Polysorbate 80 are removed from the supernatant by adsorption to an
adequate quantity of Amberlite XAD-4 resin. After adsorption of the detergents, the Amberlite resin is removed by filtration. PBS is added and the final suspension is sterilised by filtration which is the Monovalent Bulk vaccine.

The manufacture of the drug product (=final lot) involves blending four monovalent bulks (one per strain), and diluting the drug substance with buffers to produce the final (=quadrivalent) bulk. The final bulk is filled into single-dose syringes, using an Isolator filling machine to produce the final product.

15 CLINICAL TRIALS

15.1 Trial Design and Study Demographics

Table 3. - Summary of patient demographics for clinical trials in prophylaxis of influenza

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n*)</th>
<th>Mean age (Range)</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFQ3001</td>
<td>Randomized, double-blind and active-controlled study in which the quadrivalent (QIV) influenza vaccine was compared to two trivalent (TIV) influenza vaccines, containing the B-strain of either Yamagata (Yam) or Victoria (Vic) lineage</td>
<td>0.5 mL, intramuscular</td>
<td>1,980</td>
<td>61 years (range 18-91 years)</td>
<td>QIV adults: 44% male&lt;br&gt;QIV elderly: 42% male&lt;br&gt;TIV adults: 46% male (Vic) 39% male (Yam)&lt;br&gt;TIV elderly: 44% male (Vic) 46% male (Yam)</td>
</tr>
<tr>
<td>INFQ3002</td>
<td>Randomized, double-blind and active-controlled study in which the quadrivalent (QIV) influenza vaccine was compared to two trivalent (TIV) influenza vaccines, containing the B-strain of either Yamagata (Yam) or Victoria (Vic) lineage</td>
<td>0.5 mL, intramuscular</td>
<td>1,200</td>
<td>7.6 years (range 3-17 years)</td>
<td>QIV: 52.0% male&lt;br&gt;TIV: 48.8% male (Vic) 54.6% male (Yam)</td>
</tr>
</tbody>
</table>

*Total number of randomized subjects.

In general, the demographics of subjects were comparable in all vaccination groups.
Subjects at risk for complications of influenza due to their baseline health status were 13.8% of non-elderly adults and 45.2% of elderly adults who were vaccinated with QIV, and 9.5% and 40.2% of the non-elderly adults and elderly adults vaccinated with TIV.

Subjects at risk for complications of influenza due to their baseline health status were 14.9% and 15.4% of children and adolescents with QIV and TIV, respectively.

15.2 Study Results

Immunogenicity in Adults

Study INFQ3001 was a randomized, double-blind, active-controlled study in adult, stratified 1:1 for age into adults (≥18 to ≤60 years) and elderly (≥61 years) cohorts, to assess the safety and immunogenicity of INFLUVAC® TETRA (QIV) and its noninferiority to TIV INFLUVAC®. The number of subjects randomly assigned to the vaccine groups were 1,538 to QIV, 221 to the TIV formulation containing a B-strain of the Victoria lineage and 221 to the TIV formulation containing a B-strain of the Yamagata lineage. HI antibody response to each of the vaccine antigens were evaluated at 21 days post-vaccination.

Primary Efficacy Variables

The noninferiority of QIV to TIV with respect to the induced immunogenicity against the shared strains was tested by comparing the postvaccination geometric means of the HI titers against these strains between the quadrivalent formulation and the trivalent formulations (See Table 4).

For all four strains, the upper limit of the 95% confidence interval for the geometric mean ratio (GMR; TIV versus QIV) fell below the predefined noninferiority margin of 1.5, meaning that the noninferiority of QIV to TIV was demonstrated.

Table 4. - Noninferiority of QIV versus TIV against shared strains based on geometric mean HI titers at 21 days post-vaccination in adults 18 years of age and older – Per-Protocol Sample – Study INFQ3001

<table>
<thead>
<tr>
<th>Strain</th>
<th>QIV</th>
<th>TIV</th>
<th>TIV/QIV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>GMT</td>
<td>N</td>
</tr>
<tr>
<td>A (H1N1)</td>
<td>1511</td>
<td>186.6</td>
<td>433</td>
</tr>
<tr>
<td>A (H3N2)</td>
<td>1524</td>
<td>393.1</td>
<td>436</td>
</tr>
<tr>
<td>B-Victoria</td>
<td>1521</td>
<td>152.9</td>
<td>215</td>
</tr>
<tr>
<td>B-Yamagata</td>
<td>1520</td>
<td>102.1</td>
<td>215</td>
</tr>
</tbody>
</table>

QIV contained 2014/2015 northern hemisphere virus like strains A/California/7/2009 (H1N1)pdm09; A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012-like virus (TIV(Yam)); and B/Brisbane/60/2008-like virus (TIV(Vic)). Per-protocol sample: all subjects who were included in the full analysis sample without major protocol violations.

Adjusted GMR and 95% CI were calculated using analysis of variance on the log-transformed titers at the Day 22 visit with age group, country, center, and vaccine group included as factors in the model.

N = Number of subjects with non-missing data; CI = confidence interval; GMT = geometric mean titer; GMR = geometric mean ratio; HI = hemagglutinin inhibition; Vic = Victoria B strain; Yam = Yamagata B strain.

Noninferiority of QIV to TIV could be concluded if for all four strains the upper limit of the 95% CI fell below 1.5.

a HI titer data of the two trivalent formulations were pooled for the two A-strains.
b Data for B Vic
c Data for B Yam
d TIV(Vic)/QIV
e TIV(Yam)/QIV
Secondary Efficacy Variables

The secondary efficacy objective of study INFQ3001 was to demonstrate the superiority of QIV to TIV with respect to the induced immunogenicity against the alternate-lineage B-strains. This was tested by comparing the post-vaccination geometric means of the HI titers against the alternate-lineage B-strains between the QIV and the two TIV formulations (See Table 5).

For both B-strain lineages, the GMT of the TIV group was less than half of the GMT in the QIV group: 64.1 versus 153.1 (B-Victoria lineage) and 47.2 versus 101.9 (B-Yamagata lineage). Both differences were statistically significant (P < 0.0001, both comparisons). Thus, the HI antibody responses elicited by the B-strain antigens were superior to the antibody responses elicited by cross-reactivity antigens of the alternate B-strain lineages. The results for the per-protocol (PP) subject sample were similar to the full analysis (FA) subject sample.

Table 5. - Superiority of QIV versus TIV against the alternate lineage B-Strains based on the postvaccination geometric mean HI titers in adults 18 years of age and older – Full Analysis Sample – Study INFQ3001

<table>
<thead>
<tr>
<th>Strain</th>
<th>QIV</th>
<th>TIV</th>
<th>TIV/QIV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>GMT</td>
<td>N</td>
</tr>
<tr>
<td>B-Victoria</td>
<td>1526</td>
<td>153.1</td>
<td>218</td>
</tr>
<tr>
<td>B-Yamagata</td>
<td>1525</td>
<td>101.9</td>
<td>220</td>
</tr>
</tbody>
</table>

The superiority of QIV to TIV for induced immunogenicity against the alternate-lineage B strains was tested by comparing the Day 22 GMT HI titers against the alternate-lineage B strains between the quadrivalent formulation and the two trivalent formulations, using an ANOVA for the log-transformed titers, with age group and center as factors in the model. Both comparisons will be done at the two-sided significance level 0.05.

QIV contained 2014/2015 northern hemisphere virus like strains A/California/7/2009 (H1N1)pdm09; A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012-like virus (TIV(Yam)); and B/Brisbane/60/2008-like virus (TIV(Vic)). Per-protocol sample: all subjects who were included in the full analysis sample without major protocol violations. N = Number of subjects with non-missing data; CI = confidence interval; GMT = geometric mean titer; GMR = geometric mean ratio; HI = hemagglutinin inhibition; Vic = Victoria B strain; Yam = Yamagata B strain.

Immunogenicity in Children and Adolescents

Study INFQ3002 was a randomized, double-blind, active-controlled immunogenicity study in children and adolescents aged 3–17 years. It enrolled primed subjects, i.e., children and adolescents aged 9 to 17 years as well as those aged 3 to 8 years who had received ≥ two doses of a seasonal influenza vaccine at least one month apart; and unprimed subjects, i.e., children aged 3 to 8 years who had not previously received ≥ 2 doses of a seasonal influenza vaccine at least one month apart. Primed subjects were administered a single dose. Unprimed subjects were administered two doses 4 weeks apart. The number of subjects that were vaccinated is 1,200 in total (804 primed subjects and 396 unprimed subjects): 402 QIV, 404 TIV(Vic), 394 TIV(Yam).

Primary Efficacy Variables

The noninferiority of QIV to TIV with respect to the induced immunogenicity against the shared strains was tested by comparing the Day 29 (primed subjects), or Day 57 (unprimed subjects)
geometric means of the HI titers against these strains between the QIV and the TIV formulations. Non-inferiority was inspected by calculating for each of the four strains a two-sided 95% confidence interval of the geometric mean ratio (GMR) for the contrast TIV versus QIV, using an analysis of variance (ANOVA) model for the log-transformed titers.

For all four strains, the upper limit of the 95% confidence interval for the geometric mean ratio (GMR; TIV versus QIV) fell below the predefined noninferiority margin of 1.5, meaning that the noninferiority of QIV to TIV was demonstrated (see Table 4a).

Table 4a. - Noninferiority of QIV versus TIV against shared strains based on postvaccination geometric mean HI titers in children and adolescents 3 to 17 year of age – Per-Protocol Sample – Study INFQ3002

<table>
<thead>
<tr>
<th>Strain</th>
<th>QIV</th>
<th>TIVa</th>
<th>TIVa/QIV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>GMT</td>
<td>N</td>
</tr>
<tr>
<td>A (H1N1)</td>
<td>388</td>
<td>548.9</td>
<td>774</td>
</tr>
<tr>
<td>A (H3N2)</td>
<td>388</td>
<td>1150</td>
<td>774</td>
</tr>
<tr>
<td>B-Victoria</td>
<td>388</td>
<td>302.6</td>
<td>393</td>
</tr>
<tr>
<td>B-Yamagata</td>
<td>388</td>
<td>277.6</td>
<td>381</td>
</tr>
</tbody>
</table>

QIV contained 2014/2015 northern hemisphere virus like strains A/California/7/2009 (H1N1)pdm09; A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012-like virus (TIV(Vic)); and B/Brisbane/60/2008-like virus (TIV(Vic)). Per-protocol sample: all subjects who were included in the full analysis sample without major protocol violations. Adjusted GMR and 95% CI were calculated using analysis of variance on the log-transformed titers at the Day 22 visit with age group, country, center, and vaccine group included as factors in the model.

Secondary Efficacy Variables

The superiority of QIV to TIV with respect to the induced immunogenicity against the alternate-lineage B strains was tested by comparing the Day 29 (primed subjects), or Day 57 (unprimed subjects) geometric means titers against the alternate-lineage B strains between the QIV and the TIV formulation, using the same ANOVA model as for the primary analysis. Both comparisons were done at the two-sided significance level 0.05.

The HI antibody responses elicited by the B-strain antigens were superior to the antibody responses elicited by cross-reactivity antigens of the alternate B-strain lineages in subjects 3 to 17 years of age (see Table 5a). The results for the per-protocol (PP) subject sample were similar to the full analysis (FA) subject sample.

Table 5a. - Superiority of QIV versus TIV against the alternate lineage B-Strains based on the postvaccination geometric mean HI titers in children and adolescents 3 to 17 year of age – Full Analysis Sample – Study INFQ3002
<table>
<thead>
<tr>
<th>Strain</th>
<th>QIV</th>
<th>TIV</th>
<th>TIV/QIV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>GMT</td>
<td>N</td>
</tr>
<tr>
<td>B-Victoria</td>
<td>396</td>
<td>306.7</td>
<td>389</td>
</tr>
<tr>
<td>B-Yamagata</td>
<td>396</td>
<td>280.8</td>
<td>399</td>
</tr>
</tbody>
</table>

The superiority of QIV to TIV for induced immunogenicity against the alternate-lineage B strains was tested by comparing the Day 22 GMT HI titers against the alternate-lineage B strains between the quadrivalent formulation and the two trivalent formulations, using an ANOVA for the log-transformed titers, with age group and center as factors in the model. Both comparisons will be done at the two-sided significance level 0.05.

QIV contained 2014/2015 northern hemisphere virus like strains A/California/7/2009 (H1N1)pdm09; A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012-like virus (TIV(Yam)); and B/Brisbane/60/2008-like virus (TIV(Vic)). Per-protocol sample: all subjects who were included in the full analysis sample without major protocol violations. N = Number of subjects with non-missing data; CI = confidence interval; GMT = geometric mean titer; GMR = geometric mean ratio; HI = hemagglutinin inhibition; Vic = Victoria B strain; Yam = Yamagata B strain.

### 17 NON-CLINICAL TOXICOLOGY

Specific pre-clinical studies have not been conducted for quadrivalent seasonal influenza vaccine, however for the toxicological characteristics of the vaccine formulation, reference is made below to study results obtained with trivalent and monovalent seasonal influenza vaccine.

Repeated dose toxicity was investigated in male and female rabbits using a seasonal monovalent (trivalent) vaccine, which also included an adjuvanted influenza vaccine. General conclusion of this study is that the seasonal influenza vaccine used in this study did not show any systemic toxicity, when given as 3 subsequent vaccinations over the course of 4 weeks. Reproductive and developmental toxicity was investigated using trivalent seasonal vaccine. No unusual results were obtained, and the safety of the vaccine in this respect was confirmed. Given the similarity of the quadrivalent vaccine with the trivalent (or monovalent) vaccine that was used for these studies, it is considered justified to extrapolate the results from the trivalent to the quadrivalent vaccine.

### 18 SUPPORTING PRODUCT MONOGRAPHS

1) INFLUVAC\(^\circledR\) influenza vaccine, surface antigen, inactivated, Suspension for Injection
   Each 0.5 mL pre-filled syringe contains neuraminidase and 15 mcg hemagglutinin of each virus strain as recommended by the WHO and NACI. Submission control 212659, Product Monograph, BGP Pharma ULC. May 1, 2018.
INFLUVAC TETRA
Quadrivalent influenza vaccine, surface antigen, inactivated suspension for injection in pre-filled syringes

Read this carefully before you receive INFLUVAC TETRA. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about INFLUVAC TETRA.

Serious Warnings and Precautions
- INFLUVAC TETRA should not be used in individuals who are allergic to eggs, previous doses of the flu vaccine, or any components of the flu vaccine.

What is INFLUVAC TETRA used for?
- INFLUVAC TETRA is a vaccine used to prevent adults and children 3 years of age and older from developing influenza (the flu).

How does INFLUVAC TETRA work?
Like other influenza vaccines, INFLUVAC TETRA causes the body to produce antibodies against the virus. This means that when your body is exposed to the flu virus, your body is able to defend itself. The antibodies stop the attacking virus. You cannot catch influenza from INFLUVAC TETRA since it only contains portions of the inactivated virus, and not the whole live virus. Your body takes 10 to 21 days to produce antibodies after vaccination. Therefore, if you are exposed to influenza immediately before or after your vaccination, you could still develop the illness. The vaccine will not protect you against the common cold, even though some of the symptoms are similar to influenza. Influenza viruses change all the time, so different vaccines may be made every year. To stay protected against influenza, you need to be re-vaccinated every year before the winter season.

It is particularly important for some groups of people to be vaccinated. These include people with certain medical conditions, elderly people, people who are likely to be exposed to the infection and people on certain medications. If you are in doubt as to whether you should be vaccinated, talk to your local health care professionals.

What are the ingredients in INFLUVAC TETRA?
Medicinal ingredients: INFLUVAC TETRA complies with the World Health Organization (WHO) and National Advisory Committee on Immunization (NACI) recommendations for vaccination in the northern hemisphere for the 2020/2021 season.

Each 0.5 mL pre-filled syringe for injection contains neuraminidase and 15 mcg hemagglutinin of each of the following virus strains:
- an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
- an A/Hong Kong/2671/2019 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Non-medicinal ingredients: Calcium chloride dihydrate, disodium phosphate dihydrate, magnesium chloride hexahydrate, potassium chloride, potassium dihydrogen phosphate, sodium chloride, water for injection and trace amounts of cetyltrimethyl ammonium bromide, chicken protein, eggs, formaldehyde, gentamicin sulphate (or neomycin sulphate, polymyxin B sulphate), hydrocortisone, polysorbate 80, sodium citrate, sucrose and tylosine tartrate.

Do not use INFLUVAC® TETRA if:
- INFLUVAC® TETRA vaccine is made in eggs; therefore this vaccine should not be given to anyone with allergies and especially severe allergies (anaphylactic reactions) to chicken eggs or egg products.
- INFLUVAC® TETRA should not be given to people who have allergies to the active substances, to any of the excipients and to residues of eggs, chicken protein, formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin. For a complete listing of excipients, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.
- Anyone who has experienced allergic reactions to a previous dose of influenza vaccine SHOULD NOT be vaccinated with INFLUVAC® TETRA.

To help avoid side effects and ensure proper use, talk to your healthcare professional if:
- you have a fever, or you think you may be getting a fever;
- you had a serious reaction to any flu vaccine in the past;
- you have experienced any health problems;
- you are pregnant;
- you are currently on any medication (i.e., immunosuppressants, anticoagulants such as warfarin).
- you have experienced fainting, feeling faint or other stress related reactions with a previous injection.

How to take INFLUVAC® TETRA:

INFLUVAC® TETRA should only be given by a health care professional.

Usual dose:

Adults: 0.5 mL, single dose.

Children (3 years of age and older): 0.5 mL. For children less than 9 years of age who have not previously been vaccinated, a second dose of 0.5 mL should be given after an interval of at least 4 weeks.

The safety and efficacy of INFLUVAC® TETRA have not been established in children less than 3 years of age.

INFLUVAC® TETRA comes as a 0.5 mL suspension, ready for intramuscular or deep subcutaneous injection. Allow the vaccine to reach room temperature before use. Shake well before use.
**Overdose:**
Overdosage is unlikely to have any bad effect.

If you think you have taken too much INFLUVAC® TETRA, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

**What are possible side effects from using INFLUVAC® TETRA?**

These are not all the possible side effects you may feel when taking INFLUVAC® TETRA. If you experience any side effects not listed here, contact your healthcare professional.

Occasionally people have side effects with influenza vaccines. The most common of these are fever, feeling unwell, irritability (in children aged 3 to 5 years old), shivering, tiredness, headache, sweating, muscle or joint pain, and warmth. Skin reactions include redness, swelling, pain, ecchymosis (blue/black staining of the skin), a hardening of the skin at the injection site and itching.

These reactions will normally disappear without treatment in a day or two.

Rarely, neuralgia (nerve pain), paresthesia (numbness and tingling), convulsions (seizures) and temporary thrombocytopenia (a blood disorder) have been reported. In rare cases, allergic reactions may lead to shock.

Very rarely, vasculitis (inflammation of blood vessels) temporarily affecting the kidneys, neurological disorders (affecting the nerves and brain) such as encephalomyelitis, neuritis and Guillain Barré syndrome have been reported.

Allergic reactions (this might include but is not limited to breathing or swallowing difficulties, or swelling in the face or skin), and temporary enlargement of the lymph nodes have been reported.

<table>
<thead>
<tr>
<th>Serious side effects and what to do about them</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom / effect</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>COMMON</strong></td>
</tr>
<tr>
<td>Fever</td>
</tr>
<tr>
<td>Feeling unwell</td>
</tr>
<tr>
<td>Shivering</td>
</tr>
<tr>
<td>Tiredness</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Sweating</td>
</tr>
<tr>
<td>Muscle or joint pain</td>
</tr>
<tr>
<td>Skin Reactions</td>
</tr>
<tr>
<td>Redness</td>
</tr>
<tr>
<td>Swelling</td>
</tr>
<tr>
<td>Pain</td>
</tr>
<tr>
<td>Ecchymosis</td>
</tr>
</tbody>
</table>
(blue/ black staining of the skin)
Reddening of the skin at the injection site | X |

**UNCOMMON**
- Nerve pain | X |
- Numbness and tingling | X |
- Convulsions (seizures) | X |
- Temporary thrombocytopenia (a blood disorder) | X |
- Allergic reactions | X |
- Inflammation of blood vessels temporarily affecting the kidneys | X |
- Brain disorders | X |
- Guillain Barré syndrome | X |

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### Reporting Suspected Side Effects

**For the general public:**
Should you experience a side effect following immunization, please report it to your doctor, nurse, or pharmacist.
Should you require information related to the management of the side effect, please contact your healthcare provider. The Public Health Agency of Canada, Health Canada and BGP Pharma ULC cannot provide medical advice.

**For healthcare professionals:**
If a patient experiences an adverse event following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory ([http://www.phac-aspc.gc.ca/im/aeﬁ-essi-form-eng.php](http://www.phac-aspc.gc.ca/im/aeﬁ-essi-form-eng.php)) and send it to your local Health Unit.

### Storage:
Store INFLUVAC® TETRA at 2 to 8°C (in a refrigerator).

Do not freeze. Store in the original package in order to protect from light.

Do not use after the expiry date.

This vaccine is effective against this year's 2020/2021 influenza virus.

Keep out of reach and sight of children.

### If you want more information about INFLUVAC® TETRA:
- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](http://www.phac-aspc.gc.ca/im/aeﬁ-essi-form-eng.php); the manufacturer’s website [www.mylan.ca](http://www.mylan.ca), or by calling 1-844-596-9526.